What Goldar (Tibolone) Treats: Main Uses and Benefits

Goldar (Tibolone) is a synthetic hormonal compound used primarily to manage the physical and psychological changes associated with the menopause. Unlike traditional hormone replacement therapy (HRT) that uses separate estrogens and progestogens, Tibolone is a single molecule that breaks down into metabolites with estrogenic, progestogenic, and androgenic effects on different tissues in the body.

Relief of Menopausal Symptoms

The primary use of Goldar is to alleviate the symptoms caused by the decline in natural estrogen levels after menopause. These symptoms, often referred to as vasomotor symptoms, occur as the body adjusts to a new hormonal balance.

• Hot Flushes and Night Sweats: It helps regulate the body's temperature control mechanisms, reducing the frequency and severity of sudden heat sensations and perspiration.
• Vaginal Atrophy: The medication helps maintain the thickness and moisture of the vaginal lining, addressing dryness, itching, or discomfort during sexual activity.
• Mood Stability: By stabilizing hormonal fluctuations, it may assist in managing irritability and depressed mood associated with the menopausal transition.

Prevention of Postmenopausal Osteoporosis

As estrogen levels drop, bone density can decrease rapidly, leading to a higher risk of fractures. Goldar is utilized to prevent bone loss in postmenopausal women who are at high risk of future fractures.

• Maintenance of Bone Density: The estrogenic activity of the medication helps inhibit the breakdown of bone tissue.
• Structural Support: By preserving bone mineral density, it helps maintain skeletal strength during the years following the cessation of menstruation.

Benefits of Tissue-Specific Action

A defining characteristic of Goldar is its tissue-specific activity, which offers distinct clinical benefits compared to other forms of hormonal support:

• Endometrial Protection: Its progestogenic activity prevents the overgrowth of the uterine lining (endometrium), which means that, for most women, a separate progestogen is not required to prevent thickening of the uterus.
• Breast Tissue Neutrality: The medication is designed to have a neutral effect on breast density, which may be a consideration for those monitoring breast health changes.
• Libido and Well-being: Due to its mild androgenic properties, some individuals experience an improvement in sexual desire and overall energy levels.

Official Regulatory Eligibility Profile

Goldar (Tibolone) is officially indicated for use only by postmenopausal women to treat symptoms of estrogen deficiency. A natural menopause must have occurred at least 12 months prior to starting treatment. For women who have undergone a surgical menopause, treatment may begin immediately.

Contraindicated Populations	Conditions in which the medicine must NOT be used
Pregnant or breastfeeding women	Known or suspected estrogen-dependent malignant tumours (e.g., endometrial cancer)
Known, past, or suspected breast cancer	Untreated endometrial hyperplasia or undiagnosed vaginal bleeding
Known thrombophilic disorders	Active or past history of venous thromboembolism (DVT, PE)
Acute liver disease or liver function tests that have failed to return to normal	Active or recent arterial thromboembolic disease (e.g., stroke, heart attack)

Age-Related Eligibility: There is no relevant use in the pediatric population. The decision to prescribe to women over 60 years must include careful consideration of the risk of stroke, and there is limited experience in treating women over 65 years.

The official interaction profile for Goldar (Tibolone) is defined by pharmacokinetic and pharmacodynamic constraints documented in regulatory labeling. The following table summarizes key interaction patterns.

Classification	Interacting Agents	Official Outcome
Metabolic (CYP3A4)	Potent Enzyme Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin)	Decreased Tibolone serum concentration and reduced effectiveness.
Pharmacodynamic	Anticoagulants (e.g., Warfarin)	Enhanced anticoagulant effect, requiring close monitoring.
Herbal/Supplement	St John's Wort (Hypericum perforatum)	Decreased Tibolone exposure due to enzyme induction.

Regulatory documentation classifies certain co-administrations as having significant risk. Co-administration of a separate Progestogen is restricted by regulatory bodies. Furthermore, combinations with Aromatase Inhibitors and other Estrogen Agonist/Antagonists are advised to be avoided. A required procedural constraint is documented for elective surgery: treatment must be stopped 4 to 6 weeks prior to any major procedure or prolonged immobilization. This mandated timing is necessary to mitigate the risk of venous thromboembolism. These documented interactions establish the product's official constraints regarding co-administered substances, surgical planning, and patient procedural status.

How Goldar (Tibolone) Works: Mechanism of Action

Goldar (Tibolone) is an inactive pro-drug that is converted by local enzymes into three distinct active metabolites. The drug's unique activity stems from the selective way these three metabolites activate Estrogen, Progesterone, and Androgen Receptors across different tissues.

Enzyme-Controlled Selective Receptor Activation

The mechanism is defined by tissue-specific metabolism. Enzymes in different body compartments, such as bone and the uterine lining, dictate the balance of the three active metabolites that are formed. This process yields metabolites that exhibit selective binding to multiple hormone receptors, which modulates pathways across the neuroendocrine system.

Dual Action: Bone Pathways and Central Thermoregulation

The estrogenic metabolites selectively activate Estrogen Receptors ( ER) in bone and the brain's thermoregulatory center. In bone, this molecular signal suppresses mediators of bone breakdown, a process that modulates the bone remodeling cycle. In the central nervous system, this ER activity modulates the vasomotor control centers and affects central thermoregulation pathways.

Functional Endometrial Neutrality

The metabolites also activate the Progesterone Receptor ( PR) in the uterine lining (endometrium). This progestogenic effect functionally counteracts the proliferative signals that would otherwise be initiated by the drug's estrogenic activity. This mechanism facilitates a state of quiescence or atrophy in the tissue, a consequence of the diminished proliferative signaling in the uterus.

How to Use Goldar (Tibolone)

Goldar, containing the active ingredient Tibolone, is administered exclusively via the oral route as a 2.5 mg tablet. Usage instructions establish a continuous, standardized regimen that dictates both the daily dose and the required timing for initiation. The standard dose is one 2.5 mg tablet once daily. This regimen is continuous, meaning the tablet is taken every day without interruption, and the structure of the drug is such that a separate progestogen is not required.

Administration Requirements

Field	Official Instruction
Dose & Frequency	2.5 mg taken once daily in a continuous regimen.
Preparation	Tablet must be swallowed whole with a drink and should not be chewed or crushed.
Timing	Should be taken preferably at the same time every day. Can be taken with or without food.

Procedural Constraints

The initiation of treatment requires specific timing. Following natural menopause, Goldar should not be started until at least 12 months have passed since the last natural menstrual bleed. However, if treatment follows a surgical menopause, it may be commenced immediately.

The protocol for a missed dose is as follows: if a dose is missed, it should be taken immediately unless the next scheduled dose is less than 12 hours away. In this specific case, the missed dose must be skipped, and the regimen should continue with the next dose at the regular time. For patients undergoing elective surgery, it is advised to temporarily stop taking the tablet 4 to 6 weeks prior if prolonged immobilization is anticipated.

Research evidence / Overview of studies for Goldar (Tibolone)

---

Evidence for Symptoms Associated with Menopause

Research exploring the use in postmenopausal women with symptoms related to estrogen deficiency has been applied in studies examining patient-reported experiences. Short-term and intermediate-term Randomized Controlled Trials (RCTs) were conducted and evaluated in Systematic Reviews to monitor outcomes describing physical discomfort, such as hot flashes and excessive sweating. These studies were applied in research contexts involving fluctuating or unstable symptoms, including those that are relevant in trials assessing short-term or episodic symptom patterns.

Studies report patterns observed in the measured changes to symptom severity and frequency. These research patterns are relevant in evidence describing how symptoms are measured. While research provides insight into short-term changes, evidence for long-term consistency remains limited for many individuals.

Research on Urogenital Symptom Evaluation

Goldar (Tibolone) was studied for outcomes linked to inflammatory or irritative states, specifically symptoms such as vaginal dryness and irritation. This research typically examined patient-reported outcomes describing perceived discomfort. These studies often monitored responses over defined time intervals, but for many trials, urogenital changes were secondary outcomes, reflecting that research effort primarily targeted other endpoints. Consequently, data are still emerging, and certainty remains low for a dedicated, long-term understanding of these specific issues.

---

Evidence for Bone Health and Osteoporosis Prevention

The medicine was evaluated in studies observing responses over defined time intervals to understand its role in bone health. Research has explored outcomes related to systemic or functional imbalance, specifically bone loss and the risk of fracture, in postmenopausal women. Intermediate-term RCTs monitored changes in Bone Mineral Density (BMD) at the hip and spine. Furthermore, large-scale, long-term observational settings evaluated daily-life functioning by tracking the incidence of major fractures over several years.

Studies report how symptoms evolved in the observed populations, indicating patterns observed in the measurement of BMD compared to placebo, findings that contribute to the broader evidence landscape. Regarding fracture risk, studies monitored patterns related to the incidence of vertebral fractures in some studies. However, the available data for long-term outcomes, particularly for reducing the risk of hip fracture, remain limited.

Key Studies & References

1. Tibolone: benefit-risk balance (MHRA Drug Safety Update)

Common questions about Goldar (Tibolone) (FAQ)

---

Q: Can men use Goldar (Tibolone) for any reason?

Official regulatory documents explicitly state that the medicine is indicated solely for use in postmenopausal women. The purpose is to treat symptoms resulting from estrogen deficiency following the cessation of menstrual periods.

Q: How quickly does Goldar (Tibolone) start to show effects?

According to studies, the medicine's effects are often measured over several weeks or months. While some individuals may notice changes earlier, clinical trial evidence assesses symptom improvement over defined short-term and intermediate-term intervals.

Q: How long do most people stay on Goldar (Tibolone)?

There is no strict regulatory-mandated maximum duration for the use of this medicine. Official documents do, however, note that the likelihood of certain serious adverse effects, such as breast and endometrial cancer, may increase with the duration of use.

Q: Does Goldar (Tibolone) interact with blood pressure medication?

Official safety documentation indicates that this medicine may raise blood pressure in some users. Regulatory documents indicate that monitoring blood pressure is considered appropriate due to this effect.

Q: Can I drink alcohol while taking Goldar (Tibolone)?

Yes, official patient information generally indicates that consuming alcohol is permissible while taking Goldar (Tibolone). Regulatory documents do not contain specific warnings regarding the use of alcohol with this medicine.

Q: Is Goldar (Tibolone) prescribed in countries outside of the United States?

Yes, the medicine holds official authorization in numerous regions worldwide. Its regulatory status is documented by official bodies such as the European Medicines Agency (EMA), the United Kingdom’s MHRA, and the Australian TGA.

Q: What kind of monitoring or tests are usually done while on Goldar (Tibolone)?

Regulatory documentation indicates that routine physical examinations are necessary while using the medicine. These examinations typically include regular breast exams and gynecological check-ups, in addition to monitoring blood pressure and liver function.

Q: Can I drive or operate machinery safely while taking Goldar (Tibolone)?

Regulatory information states that the medicine is not known to affect alertness or concentration. However, as with most medications, observing any individual effects before driving or operating machinery is generally noted as appropriate.

Q: What does 'systemic' mean in the context of Goldar (Tibolone) use?

When a medicine is described as systemic, it means that its active compounds affect the entire body. Goldar (Tibolone) is systemic because it is taken as an oral tablet and its active metabolites travel through the bloodstream, acting in various tissues.

Q: What are the official guidelines regarding follow-up appointments when taking Goldar (Tibolone)?

Authoritative medical guidelines suggest that routine follow-up examinations should be conducted at regular intervals. These appointments, which may occur yearly or every two years, are for checking key clinical factors and assessing individual risk.

Q: What is the main difference between Goldar and traditional HRT?

Goldar is classified as a Selective Tissue Estrogenic Activity Regulator (STEAR), which is a single-component pro-drug. Its unique mechanism suggests that, unlike many traditional Hormone Replacement Therapies, a separate progestogen is not required as part of the regimen.

Q: Will Goldar (Tibolone) affect my moods or emotional state?

Official labeling notes the potential for a positive, supportive effect on mood and sexual well-being. However, as with any medicine affecting hormonal pathways, regulatory documents also list less common adverse effects such as depression.

Q: Is there a risk of hair loss associated with Goldar (Tibolone)?

Regulatory safety documents list Hirsutism (unusual hair growth) as a documented common adverse effect. Hair loss (alopecia) is not officially listed in the common or uncommon adverse reaction profiles.

Q: Why do some doctors choose Goldar (Tibolone) over estrogen-only therapy?

The official product information notes that the drug is a single component that is converted into active metabolites that do not require the co-administration of a separate progestogen. The medicine is also noted for its potential supportive effect on mood and sexual well-being.

Q: Does Goldar (Tibolone) contain estrogen?

The active ingredient, Tibolone, is an inactive pro-drug and a synthetic steroid analog; it does not contain estrogen directly. However, it is rapidly converted by the body into three active metabolites that activate Estrogen Receptors in certain tissues.

Q: Can Goldar (Tibolone) cause stomach upset or digestive issues?

The official safety profile lists abdominal pain as a common adverse effect associated with the use of the medicine. Regulatory documents also note that less common side effects may include general gastro-intestinal upset.

Q: Is Goldar (Tibolone) used for treating symptoms other than vasomotor and bone health?

Yes, official information states that the medicine is also studied for outcomes linked to urogenital symptoms, such as vaginal dryness. It is also noted for its potential supportive effect on mood and sexual well-being.

Q: What are the typical expected outcomes of using Goldar (Tibolone)?

Expected outcomes, based on clinical studies, include the modulation of physical discomfort (such as hot flashes and sweating). The medicine also provides support for bone mineral density and has potential supportive effects on mood and sexual well-being.

Q: Are there specific symptoms that Goldar (Tibolone) is most effective for?

Clinical research has primarily found strong supporting evidence for the medicine’s effects on symptoms of physical discomfort associated with estrogen deficiency, such as hot flashes and excessive sweating. Evidence also supports its role in the modulation of bone mineral density.

Q: What is the general safety classification of Goldar (Tibolone)?

Goldar (Tibolone) is regulated as a prescription-only medication. The official safety profile details a categorization of adverse effects (common and uncommon) and lists serious risks, including Stroke, VTE, Endometrial Cancer, and Breast Cancer.

Q: What if I start having headaches after beginning Goldar (Tibolone)?

Headaches are listed as a possible uncommon effect in regulatory documents. Official label information states that the medicine should be discontinued upon the occurrence of a new onset of migraine-type headache.

How to Store and Dispose of Goldar (Tibolone)

Goldar (tibolone) must be stored and handled according to specific regulatory guidelines to maintain its stability and ensure public safety.

Official Storage Conditions

Requirement	Specific Condition
Temperature	Store at a temperature not exceeding 25°C (77°F).
Protection	Must be protected from light and moisture.
Packaging	Keep the tablets in the original package.
Safety	Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Goldar tablets must not be disposed of via household waste or waste water. Regulatory instructions mandate that disposal follows local requirements for the collection of special waste or by returning the product to a pharmacist.